Abbvie Inc
NYSE:ABBV
Abbvie Inc
Treasury Stock
Abbvie Inc
Treasury Stock Peer Comparison
Competitive Treasury Stock Analysis
Latest Figures & CAGR of Competitors
Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Treasury Stock
-$6.5B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-35%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Treasury Stock
-$12.6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-100%
|
CAGR 10-Years
N/A
|
See Also
What is Abbvie Inc's Treasury Stock?
Treasury Stock
-6.5B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Treasury Stock amounts to -6.5B USD.
What is Abbvie Inc's Treasury Stock growth rate?
Treasury Stock CAGR 10Y
-35%
Over the last year, the Treasury Stock growth was -42%. The average annual Treasury Stock growth rates for Abbvie Inc have been -42% over the past three years , 23% over the past five years , and -35% over the past ten years .